|
US6358932B1
(en)
|
1994-05-31 |
2002-03-19 |
Isis Pharmaceticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
|
US6391636B1
(en)
|
1994-05-31 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
|
US6037136A
(en)
|
1994-10-24 |
2000-03-14 |
Cold Spring Harbor Laboratory |
Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
|
|
US5717100A
(en)
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
US6514977B1
(en)
|
1997-05-22 |
2003-02-04 |
G.D. Searle & Company |
Substituted pyrazoles as p38 kinase inhibitors
|
|
NZ501112A
(en)
|
1997-05-22 |
2002-10-25 |
G |
Substituted pyrazoles as p38 kinase inhibitors
|
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
|
US6204467B1
(en)
|
1998-03-24 |
2001-03-20 |
Ford Global Technologies, Inc. |
Method and apparatus for resistive welding
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US6316435B2
(en)
|
1999-02-24 |
2001-11-13 |
Supergen, Inc. |
Combination therapy for lymphoproliferative diseases
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
NZ552335A
(en)
|
2001-10-25 |
2008-11-28 |
Novartis Ag |
Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent
|
|
JP4399265B2
(ja)
|
2001-12-21 |
2010-01-13 |
ヴァーナリス（ケンブリッジ）リミテッド |
３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
|
|
EA200600495A1
(ru)
|
2003-09-23 |
2006-10-27 |
Новартис Аг |
Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
|
|
AU2004289539C1
(en)
|
2003-11-14 |
2012-06-07 |
Lorus Therapeutics Inc. |
Aryl imidazoles and their use as anti-cancer agents
|
|
CA2551948A1
(en)
|
2004-01-09 |
2005-07-28 |
Novartis Ag |
Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
|
|
MXPA06014247A
(es)
|
2004-06-10 |
2007-03-12 |
Irm Llc |
Compuestos y composiciones como inhibidores de la proteina quinasa.
|
|
WO2006102079A1
(en)
|
2005-03-17 |
2006-09-28 |
Novartis Ag |
N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
|
|
US20070099856A1
(en)
*
|
2005-05-13 |
2007-05-03 |
Gumerlock Paul H |
Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
|
|
WO2007021966A1
(en)
|
2005-08-12 |
2007-02-22 |
Synta Pharmaceuticals Corp. |
Pyrazole compounds that modulate hsp90 activity
|
|
RU2442574C2
(ru)
|
2005-08-22 |
2012-02-20 |
Новартис Аг |
ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
|
|
EP1917258A2
(en)
|
2005-08-26 |
2008-05-07 |
SmithKline Beecham Corporation |
Pyrimidinyl-pyrazole inhibitors of aurora kinases
|
|
PE20070335A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
|
CA2643066A1
(en)
|
2006-03-16 |
2007-09-20 |
Pfizer Products Inc. |
Pyrazole compounds
|
|
CN101415411A
(zh)
|
2006-04-05 |
2009-04-22 |
诺瓦提斯公司 |
用于治疗癌症的治疗剂组合
|
|
WO2007123892A2
(en)
|
2006-04-17 |
2007-11-01 |
Arqule Inc. |
Raf inhibitors and their uses
|
|
AU2007305016B2
(en)
|
2006-10-02 |
2011-11-03 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
WO2008045627A2
(en)
|
2006-10-06 |
2008-04-17 |
Irm Llc |
Protein kinase inhibitors and methods for using thereof
|
|
CA2677651A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
US20090022789A1
(en)
|
2007-07-18 |
2009-01-22 |
Supernus Pharmaceuticals, Inc. |
Enhanced formulations of lamotrigine
|
|
BRPI0815042A2
(pt)
|
2007-08-01 |
2015-02-10 |
Pfizer |
Compostos de pirazol
|
|
BRPI0818340A2
(pt)
|
2007-10-19 |
2015-04-22 |
Abbott Gmbh & Co Kg |
Produto de dispersão sólida de fármacos baseados em n-aril uréia
|
|
CA2704436C
(en)
|
2007-11-14 |
2016-01-05 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc. |
Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
WO2009115572A2
(en)
|
2008-03-21 |
2009-09-24 |
Novartis Ag |
Novel heterocyclic compounds and uses therof
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
EP2324008B1
(en)
|
2008-07-24 |
2012-05-09 |
Nerviano Medical Sciences S.R.L. |
3,4-diarylpyrazoles as protein kinase inhibitors
|
|
KR20110038159A
(ko)
|
2008-07-28 |
2011-04-13 |
길리애드 사이언시즈, 인코포레이티드 |
사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
|
|
EP2350052B1
(en)
|
2008-09-29 |
2014-08-13 |
Boehringer Ingelheim International GmbH |
Antiproliferative compounds
|
|
EP2346495B2
(en)
|
2008-10-07 |
2023-05-24 |
Kudos Pharmaceuticals Limited |
Pharmaceutical formulation 514
|
|
WO2010056662A1
(en)
|
2008-11-11 |
2010-05-20 |
University Of Washington |
Activated wnt-beta-catenin signaling in melanoma
|
|
ES2422263T3
(es)
|
2008-12-19 |
2013-09-10 |
Nerviano Medical Sciences Srl |
Pirazoles bicíclicos como inhibidores de la proteinquinasa
|
|
AR075180A1
(es)
|
2009-01-29 |
2011-03-16 |
Novartis Ag |
Formulaciones orales solidas de una pirido-pirimidinona
|
|
RU2402602C1
(ru)
*
|
2009-02-12 |
2010-10-27 |
Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН |
КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
|
|
WO2010100127A1
(en)
|
2009-03-04 |
2010-09-10 |
Novartis Ag |
Disubstituted imidazole derivatives as modulators of raf kinase
|
|
TWI532484B
(zh)
|
2009-06-08 |
2016-05-11 |
艾伯維有限公司 |
包含凋亡促進劑之固態分散劑
|
|
EP3045457B1
(en)
|
2009-06-15 |
2018-05-09 |
Nerviano Medical Sciences S.r.l. |
Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
|
|
KR101256018B1
(ko)
|
2009-08-20 |
2013-04-18 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
|
AU2011209234B2
(en)
|
2010-01-27 |
2015-05-07 |
Nerviano Medical Sciences S.R.L. |
Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
|
|
SG10201502484SA
(en)
|
2010-03-30 |
2015-05-28 |
Verseon Corp |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
|
JP5938038B2
(ja)
|
2010-08-03 |
2016-06-22 |
ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ |
ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
|
|
HUE032100T2
(en)
|
2011-03-21 |
2017-08-28 |
Valcuria Ab |
A pharmaceutical composition comprising an HDAC inhibitor and a steroid and its use
|
|
CN103608012A
(zh)
|
2011-06-14 |
2014-02-26 |
诺华股份有限公司 |
在癌症如骨髓增殖性肿瘤治疗中的帕比司他与鲁索利替尼的组合
|
|
CA2856406C
(en)
|
2011-11-23 |
2020-06-23 |
Novartis Ag |
Pharmaceutical formulations
|
|
HK1214765A1
(zh)
|
2012-11-08 |
2016-08-05 |
Novartis Ag |
包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
|